[1] Siegel RL, Miller KD, Jemal A.  Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30.   doi: 10.3322/caac.21590
[2] Knoth K, Pötter R, Jürgenliemk-Schulz IM, et al.  Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging—an analysis from the EMBRACE study[J]. Gynecol Oncol, 2020, 159(1): 136-141.   doi: 10.1016/j.ygyno.2020.07.007
[3] Liu BL, Li LX, Wang MX, et al.  Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: a single-institutional retrospective study from a prospective database[J]. Gynecol Oncol, 2019, 154(3): 583-589.   doi: 10.1016/j.ygyno.2019.07.005
[4] Wang T, Gao TT, Yang JB, et al.  Preoperative prediction of pelvic lymph nodes metastasis in early-stage cervical cancer using radiomics nomogram developed based on T2-weighted MRI and diffusion-weighted imaging[J]. Eur J Radiol, 2019, 114: 128-135.   doi: 10.1016/j.ejrad.2019.01.003
[5] Guo QF, Sun YW, Kong EQ, et al.  Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study[J]. Medicine, 2020, 99(11): e19372-.   doi: 10.1097/MD.0000000000019372
[6] Matsuo K, Machida H, Mandelbaum RS, et al.  Validation of the 2018 FIGO cervical cancer staging system[J]. Gynecol Oncol, 2019, 152(1): 87-93.   doi: 10.1016/j.ygyno.2018.10.026
[7] Sok M, Zavrl M, Greif B, et al.  Objective assessment of WHO/ECOG performance status[J]. Support Care Cancer, 2019, 27(10): 3793-3798.   doi: 10.1007/s00520-018-4597-z
[8] Klopp AH, Yeung AR, Deshmukh S, et al.  Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology—RTOG 1203[J]. J Clin Oncol, 2018, 36(24): 2538-2544.   doi: 10.1200/JCO.2017.77.4273
[9]

Chen WL, Li T, Wang J, et al. Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer[J/OL]. Cancer Manag Res, 2019, 11: 8157−8165[2020-12-16]. https://www.dovepress.com/clinical-study-of-nimotuzumab-combined-with-concurrent-radiochemothera-peer-reviewed-fulltext-article-CMAR. DOI: 10.2147/CMAR.S191134.
[10] Yang SL, Chen L, He Y, et al.  Effect of neoadjuvant chemotherapy followed by surgery for FIGO stage Ⅰ−Ⅱ cervical cancer: a meta-analysis[J]. J Int Med Res, 2020, 48(8): 300060520945507-.   doi: 10.1177/0300060520945507
[11]

Zou W, Han YY, Zhang Y, et al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage ⅠB2−ⅡB cervical cancer: a systematic review and meta-analysis[J/OL]. PLoS One, 2019, 14(11): e0225264[2020-12-16]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0225264. DOI: 10.1371/journal.pone.0225264.
[12]

Chen BX, Wang LM, Ren C, et al. The effect of neoadjuvant chemotherapy on lymph node metastasis of FIGO stage ⅠB1−ⅡB cervical cancer: a systematic review and meta-analysis[J/OL]. Front Oncol, 2020, 10: 570258[2020-12-16]. https://www.frontiersin.org/articles/10.3389/fonc.2020.570258/full. DOI: 10.3389/fonc.2020.570258.
[13] Tsuruoka S, Hamamoto Y, Takata N, et al.  Treatment response after definitive radiotherapy and outcomes in patients with locally advanced cervical cancer[J]. Brachytherapy, 2019, 18(3): 101-.   doi: 10.1016/j.brachy.2019.04.220
[14] Kim SI, Lee M, Kim HS, et al.  Minimally invasive surgery versus laparotomic surgery as a primary treatment for patients with stage ⅠA1−ⅡA2 cervical cancer[J]. Gynecol Oncol, 2019, 154(S1): S10-11.   doi: 10.1016/j.ygyno.2019.04.032
[15] Maulard A, Chargari C, Faron M, et al.  A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer[J]. Gynecol Oncol, 2020, 159(2): 534-538.   doi: 10.1016/j.ygyno.2020.08.002
[16] Melamed A, Ramirez PT.  Changing treatment landscape for early cervical cancer: outcomes reported with minimally invasive surgery compared with an open approach[J]. Curr Opin Obstet Gynecol, 2020, 32(1): 22-27.   doi: 10.1097/GCO.0000000000000598
[17] Kotsopoulos LC, Newton CL, Mould TA.  Invasive cervical cancer[J]. Obst Gynaecol Rep Med, 2020, 30(6): 167-174.   doi: 10.1016/j.ogrm.2020.03.004
[18] 骆华春, 傅志超, 沈志勇, 等.  放疗在低负荷转移性前列腺癌中的应用价值[J]. 国际放射医学核医学杂志, 2021, 45(8): 507-514.   doi: 10.3760/cma.j.cn121381-202005013-00064
Luo HC, Fu ZC, Shen ZY.  Application of radiotherapy in low burden metastatic prostate cancer[J]. Int J Radiat Med Nucl Med, 2021, 45(8): 507-514.   doi: 10.3760/cma.j.cn121381-202005013-00064
[19] Slevin F, Beasley M, Speight R, et al.  Overview of patient preparation strategies to manage internal organ motion during radiotherapy in the pelvis[J]. J Radio Pract, 2020, 19(2): 182-189.   doi: 10.1017/S1460396919000530
[20] Wang YF, Farmer M, Izaguirre EW, et al.  Association of definitive pelvic radiation therapy with survival among patients with newly diagnosed metastatic cervical cancer[J]. JAMA Oncol, 2018, 4(9): 1288-1291.   doi: 10.1001/jamaoncol.2018.2677
[21] Luo HC, Lin GS, Liao SG, et al.  Cervical cancer treated with reduced-volume intensity-modulated radiation therapy base on Sedlis criteria (NCCN vs RTOG)[J]. Br J Radiol, 2018, 91(1081): 20170398-.   doi: 10.1259/bjr.20170398
[22] Shrestha AD, Neupane D, Vedsted P.  Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review[J]. Asian Pac J Cancer Prev, 2018, 19(2): 319-324.   doi: 10.22034/APJCP.2018.19.2.319
[23] Ma YM, Zhao GL, Qi J, et al.  Neoadjuvant brachytherapy and chemotherapy followed by radical surgery for stage ⅠB2 and ⅡA cervical cancer: a retrospective comparison with chemoirradiation[J]. Mol Clin Oncol, 2018, 8(4): 617-622.   doi: 10.3892/mco.2018.1580